Dephosphorylated-uncarboxylated Matrix Gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients.
[en] Background: Matrix Gla protein (MGP) is known to act as a potent local inhibitor of vascular calcifications.
However, in order to be active, MGP must be phosphorylated and carboxylated, with this last process being
dependent on vitamin K. The present study focused on the inactive form of MGP (dephosphorylated and
uncarboxylated: dp-ucMGP) in a population of hemodialyzed (HD) patients. Results found in subjects being treated
or not with vitamin K antagonist (VKA) were compared and the relationship between dp-ucMGP levels and the
vascular calcification score were assessed.
Methods: One hundred sixty prevalent HD patients were enrolled into this observational cohort study, including
23 who were receiving VKA treatment. The calcification score was determined (using the Kauppila method) and
dp-ucMGP levels were measured using the automated iSYS method.
Results: dp-ucMGP levels were much higher in patients being treated with VKA and little overlap was found with
those not being treated (5604 [3758; 7836] vs. 1939 [1419; 2841] pmol/L, p <0.0001). In multivariate analysis,
treatment with VKA was the most important variable explaining variation in dp-ucMGP levels even when adjusting
for all other significant variables. In the 137 untreated patients, dp-ucMGP levels were significantly (p < 0.05) associated
both in the uni- and multivariate analysis with age, body mass index, plasma levels of albumin, C-reactive protein, and
FGF-23, and the vascular calcification score.
Conclusion: We confirmed that the concentration of dp-ucMGP was higher in HD patients being treated with VKA. We
observed a significant correlation between dp-ucMGP concentration and the calcification score. Our data support the
theoretical role of MGP in the development of vascular calcifications. We confirmed the potential role of the inactive
form of MGP in assessing the vitamin K status of the HD patients.
Disciplines :
Laboratory medicine & medical technology
Author, co-author :
DELANAYE, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Néphrologie
Smelten, Nicole ; Université de Liège - ULiège > Département des sciences cliniques > Néphrologie
Médart
Pottel, H
CAVALIER, Etienne ; Centre Hospitalier Universitaire de Liège - CHU > Chimie médicale
Language :
English
Title :
Dephosphorylated-uncarboxylated Matrix Gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients.
Matrix Gla protein, a new gamma-carboxyglutamic acid-containing protein which is associated with the organic matrix of bone. Price PA, Urist MR, Otawara Y, Biochem Biophys Res Commun 1983 117 765 771 10.1016/0006-291X(83)91663-7 6607731
Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G, Nature 1997 386 78 81 10.1038/386078a0 9052783
Matrix Gla protein metabolism in vascular smooth muscle and role in uremic vascular calcification. Lomashvili KA, Wang X, Wallin R, O'Neill WC, J Biol Chem 2011 286 28715 28722 10.1074/jbc.M111.251462 21705322
Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. Zebboudj AF, Imura M, Bostrom K, J Biol Chem 2002 277 4388 4394 10.1074/jbc.M109683200 11741887
Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. Murshed M, Schinke T, McKee MD, Karsenty G, J Cell Biol 2004 165 625 630 10.1083/jcb.200402046 15184399
Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. Schlieper G, Westenfeld R, Kruger T, Cranenburg EC, Magdeleyns EJ, Brandenburg VM, Djuric Z, Damjanovic T, Ketteler M, Vermeer C, Dimkovic N, Floege J, Schurgers LJ, J Am Soc Nephrol 2011 22 387 395 10.1681/ASN.2010040339 21289218
Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) species. Cranenburg EC, Koos R, Schurgers LJ, Magdeleyns EJ, Schoonbrood TH, Landewe RB, Brandenburg VM, Bekers O, Vermeer C, Thromb Haemost 2010 104 811 822 10.1160/TH09-11-0786 20694284
Matrix Gla-protein: the calcification inhibitor in need of vitamin K. Schurgers LJ, Cranenburg EC, Vermeer C, Thromb Haemost 2008 100 593 603 18841280
Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Westenfeld R, Krueger T, Schlieper G, Cranenburg EC, Magdeleyns EJ, Heidenreich S, Holzmann S, Vermeer C, Jahnen-Dechent W, Ketteler M, Floege J, Schurgers LJ, Am J Kidney Dis 2012 59 186 195 10.1053/j.ajkd.2011.10.041 22169620
Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC, Am J Kidney Dis 1996 27 394 401 10.1016/S0272-6386(96)90363-7 8604709
Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB, N Engl J Med 2000 342 1478 1483 10.1056/NEJM200005183422003 10816185
Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Jean G, Bresson E, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C, Nephrol Dial Transplant 2009 24 948 955 18852190
Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F, Circulation 2002 106 100 105 10.1161/01.CIR.0000020222.63035.C0 12093777
A plain X-ray vascular calcification score is associated with arterial stiffness and mortality in dialysis patients. Adragao T, Pires A, Birne R, Curto JD, Lucas C, Goncalves M, Negrao AP, Nephrol Dial Transplant 2009 24 997 1002 18952701
Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H, Nephrol Dial Transplant 2003 18 1731 1740 10.1093/ndt/gfg414 12937218
Vascular access calcification predicts mortality in hemodialysis patients. Schlieper G, Kruger T, Djuric Z, Damjanovic T, Markovic N, Schurgers LJ, Brandenburg VM, Westenfeld R, Dimkovic S, Ketteler M, Grootendorst DC, Dekker FW, Floege J, Dimkovic N, Kidney Int 2008 74 1582 1587 10.1038/ki.2008.458 18800030
Vitamin K: key vitamin in controlling vascular calcification in chronic kidney disease. Schurgers LJ, Kidney Int 2013 83 782 784 10.1038/ki.2013.26 23633049
Vitamins K and D status in stages 3-5 chronic kidney disease. Holden RM, Morton AR, Garland JS, Pavlov A, Day AG, Booth SL, Clin J Am Soc Nephrol 2010 5 590 597 10.2215/CJN.06420909 20167683
Subclinical vitamin K deficiency in hemodialysis patients. Pilkey RM, Morton AR, Boffa MB, Noordhof C, Day AG, Su Y, Miller LM, Koschinsky ML, Booth SL, Am J Kidney Dis 2007 49 432 439 10.1053/j.ajkd.2006.11.041 17336705
Vitamin K intake and status are low in hemodialysis patients. Cranenburg EC, Schurgers LJ, Uiterwijk HH, Beulens JW, Dalmeijer GW, Westerhuis R, Magdeleyns EJ, Herfs M, Vermeer C, Laverman GD, Kidney Int 2012 82 605 610 10.1038/ki.2012.191 22648294
Vitamin K, vertebral fractures, vascular calcifications, and mortality: VItamin K Italian (VIKI) dialysis study. Fusaro M, Noale M, Viola V, Galli F, Tripepi G, Vajente N, Plebani M, Zaninotto M, Guglielmi G, Miotto D, Dalle CL, D'Angelo A, Naso A, Grimaldi C, Miozzo D, Giannini S, Gallieni M, J Bone Miner Res 2012 27 2271 2278 10.1002/jbmr.1677 22692665
Vitamin k intake and plasma desphospho-uncarboxylated matrix Gla-protein levels in kidney transplant recipients. Boxma PY, van den Berg E, Geleijnse JM, Laverman GD, Schurgers LJ, Vermeer C, Kema IP, Muskiet FA, Navis G, Bakker SJ, de Borst MH, PLoS One 2012 7 47991 10.1371/journal.pone.0047991 23118917
Vitamin K status in chronic kidney disease: a report of a study and a mini-review. Voong K, Harrington D, Goldsmith D, Int Urol Nephrol 2013 45 1339 1344 10.1007/s11255-012-0367-x 23296791
The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Schurgers LJ, Barreto DV, Barreto FC, Liabeuf S, Renard C, Magdeleyns EJ, Vermeer C, Choukroun G, Massy ZA, Clin J Am Soc Nephrol 2010 5 568 575 10.2215/CJN.07081009 20133489
Circulating uncarboxylated matrix gla protein is associated with vitamin K nutritional status, but not coronary artery calcium, in older adults. Shea MK, O'Donnell CJ, Vermeer C, Magdeleyns EJ, Crosier MD, Gundberg CM, Ordovas JM, Kritchevsky SB, Booth SL, J Nutr 2011 141 1529 1534 10.3945/jn.111.139634 21628633
Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study. Caluwe R, Vandecasteele S, Van VB, Vermeer C, De Vriese AS, Nephrol Dial Transplant 2014 29 1385 1390 10.1093/ndt/gft464 24285428
Vitamin K supplementation and progression of coronary artery calcium in older men and women. Shea MK, O'Donnell CJ, Hoffmann U, Dallal GE, Dawson-Hughes B, Ordovas JM, Price PA, Williamson MK, Booth SL, Am J Clin Nutr 2009 89 1799 1807 10.3945/ajcn.2008.27338 19386744
Circulating matrix Gla protein is associated with coronary artery calcification and vitamin K status in healthy women. Dalmeijer GW, van der Schouw YT, Vermeer C, Magdeleyns EJ, Schurgers LJ, Beulens JW, J Nutr Biochem 2013 24 624 628 10.1016/j.jnutbio.2012.02.012 22819559
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, Kidney Int Suppl 2009 113 1 130 19644521
New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW, Atherosclerosis 1997 132 245 250 10.1016/S0021-9150(97)00106-8 9242971
Undercarboxylated matrix Gla protein is associated with indices of heart failure and mortality in symptomatic aortic stenosis. Ueland T, Gullestad L, Dahl CP, Aukrust P, Aakhus S, Solberg OG, Vermeer C, Schurgers LJ, J Intern Med 2010 268 483 492 10.1111/j.1365-2796.2010.02264.x 20804515
Renal handling of matrix Gla-protein in humans with moderate to severe hypertension. Rennenberg RJ, Schurgers LJ, Vermeer C, Scholte JB, Houben AJ, de Leeuw PW, Kroon AA, Hypertens Res 2008 31 1745 1751 10.1291/hypres.31.1745 18971553
Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol. Krueger T, Schlieper G, Schurgers L, Cornelis T, Cozzolino M, Jacobi J, Jadoul M, Ketteler M, Rump LC, Stenvinkel P, Westenfeld R, Wiecek A, Reinartz S, Hilgers RD, Floege J, Nephrol Dial Transplant 2014 29 1633 1638 10.1093/ndt/gft459 24285427
Coronary calcifications in end-stage renal disease patients: a new link between osteoprotegerin, diabetes and body mass index? Cianciolo G, La Manna G, Donati G, Persici E, Dormi A, Cappuccilli ML, Corsini S, Fattori R, Russo V, Nastasi V, Coli L, Wratten M, Stefoni S, Blood Purif 2010 29 13 22 10.1159/000245042 19816015
Uncarboxylated matrix Gla protein (ucMGP) is associated with coronary artery calcification in haemodialysis patients. Cranenburg EC, Brandenburg VM, Vermeer C, Stenger M, Muhlenbruch G, Mahnken AH, Gladziwa U, Ketteler M, Schurgers LJ, Thromb Haemost 2009 101 359 366 19190822
Undercarboxylated matrix GLA protein levels are decreased in dialysis patients and related to parameters of calcium-phosphate metabolism and aortic augmentation index. Hermans MM, Vermeer C, Kooman JP, Brandenburg V, Ketteler M, Gladziwa U, Rensma PL, Leunissen KM, Schurgers LJ, Blood Purif 2007 25 395 401 10.1159/000108629 17890861
Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography. Jono S, Ikari Y, Vermeer C, Dissel P, Hasegawa K, Shioi A, Taniwaki H, Kizu A, Nishizawa Y, Saito S, Thromb Haemost 2004 91 790 794 15045141
Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. McCabe KM, Booth SL, Fu X, Shobeiri N, Pang JJ, Adams MA, Holden RM, Kidney Int 2013 83 835 844 10.1038/ki.2012.477 23344475
Calciphylaxis in CKD and beyond. Brandenburg VM, Kramann R, Specht P, Ketteler M, Nephrol Dial Transplant 2012 27 1314 1318 10.1093/ndt/gfs015 22344774
Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. Chan KE, Lazarus JM, Thadhani R, Hakim RM, J Am Soc Nephrol 2009 20 2223 2233 10.1681/ASN.2009030319 19713308
Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Koos R, Mahnken AH, Muhlenbruch G, Brandenburg V, Pflueger B, Wildberger JE, Kuhl HP, Am J Cardiol 2005 96 747 749 10.1016/j.amjcard.2005.05.014 16169351
Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Price PA, Faus SA, Williamson MK, Arterioscler Thromb Vasc Biol 1998 18 1400 1407 10.1161/01.ATV.18.9.1400 9743228
Association of warfarin use with valvular and vascular calcification: a review. Palaniswamy C, Sekhri A, Aronow WS, Kalra A, Peterson SJ, Clin Cardiol 2011 34 74 81 10.1002/clc.20865 21298649
Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype. Schurgers LJ, Joosen IA, Laufer EM, Chatrou ML, Herfs M, Winkens MH, Westenfeld R, Veulemans V, Krueger T, Shanahan CM, Jahnen-Dechent W, Biessen E, Narula J, Vermeer C, Hofstra L, Reutelingsperger CP, PLoS One 2012 7 43229 10.1371/journal.pone.0043229 22952653
